Article

Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan.

Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences, National Health Research Institute, Miao-Li, Taiwan.
Neuroscience Letters (Impact Factor: 2.06). 11/2009; 468(3):330-3. DOI: 10.1016/j.neulet.2009.11.026
Source: PubMed

ABSTRACT The pathophysiological process of schizophrenia is still unclear. The levels of interleukine-6 (IL-6) and its receptor, soluble IL-6R, have been reported to be elevated in the plasma and cerebrospinal fluid of schizophrenic patients. In this study, we tested the association of genetic variants of IL-6 and IL-6R with schizophrenia. Genotyping of three single nucleotide polymorphisms (SNP) for each IL-6 (IL-6-1, IL-6-2, and IL-6-3) and IL-6R (rs4845617=IL-6R1, rs4553185=IL-6R2, and rs4379670=IL-6R3) gene was performed in 100 patients with schizophrenia and 113 normal controls. The polymorphisms of IL-6R2 were genotyped using Tetra-primer ARMS PCR. IL-6R3 polymorphisms were genotyped using restriction fragment length polymorphism (RFLP) with Apo I enzyme as the restriction enzyme. All other polymorphisms were genotyped using the direct sequencing method. We found a di-nucleotide haplotype block and a tri-nucleotide haplotype block in the genes of IL-6 and IL-6R, respectively. All six SNPs and their haplotypes failed to show a significant association with schizophrenia. The IL-6-2 SNP showed a nominally significant association with the positive symptoms of schizophrenia (p=0.0472). We conclude that the genetic variants of IL-6 and IL-6R are not associated with schizophrenia. In order to verify this result, further study using a larger sample size and exploring the association between the genotype of IL-6-2 and plasma level of IL-6 is recommended.

Full-text

Available from: Hsieh H. Ming, May 29, 2015
0 Followers
 · 
137 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The influence of the immune system deregu-lation on the risk of schizophrenia is increasingly recog-nized. The aim of this study was to assess the influence of serum interleukin-6 (IL-6) level together with the poly-morphism in its gene (IL6 -174G/C) and high sensitivity C-reactive protein (hsCRP) levels on clinical manifestation and cognition in schizophrenia patients. We recruited 151 patients with schizophrenia and 194 healthy control sub-jects. Psychopathology was evaluated using Operational Criteria for Psychotic Illness checklist, Positive and Neg-ative Syndrome Scale (PANSS) and Scales for Assessment of Positive and Negative Symptoms. Cognitive perfor-mance in schizophrenia patients was assessed using fol-lowing tests: Rey Auditory Verbal Learning Test, Trail Making Test, Verbal Fluency Tests, Stroop and subscales from Wechsler Adults Intelligence Scale-R-Pl (Similari-ties, Digit Symbol Coding, Digit Span Forward and Backward). Serum IL-6 and hsCRP levels were signifi-cantly higher in schizophrenia patients in comparison with healthy controls. Both hsCRP and IL-6 levels were asso-ciated with insidious psychosis onset, duration of illness and chronic schizophrenia course with deterioration. After adjustment for age, education level, number of years of completed education, illness duration, total PANSS score, depression severity and chlorpromazine equivalent, there was still a positive association between IL-6 and hsCRP levels and worse cognitive performance. The IL6 -174G/C polymorphism did not influence IL-6 level, but it was associated with the severity of positive symptoms. Our results suggest that elevated IL-6 levels may play the role in cognitive impairment and serve as potential inflamma-tory biomarker of deterioration in schizophrenia.
    European Archives of Psychiatry and Clinical Neuroscience 09/2014; DOI:10.1007/s00406-014-0533-5 · 3.36 Impact Factor
  • Source
    European Neuropsychopharmacology, Abstracts of the 26th ECNP Congress, Barcelona, Spain; 10/2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a heterogeneous disorder and its etiology remains incompletely elucidated. Among possible causes, immunological factors have been implicated in its pathogenesis and course. The inflammatory system may trigger or modulate the course of schizophrenia through complex mechanisms influencing neurodevelopment, neuroplasticity and neurotransmission. Recent studies indicate a role of excessive interleukin-6 (IL6) signaling in the pathogenesis of schizophrenia. Findings regarding changes in the circulating levels of soluble interleukin-6 receptor (sIL6R) in schizophrenia have been equivocal. The study was performed on a group of 147 trio (patients diagnosed with schizophrenia and theirs healthy parents). Polymorphisms of IL6 (rs1800795, rs1800797) and IL6R (rs4537545, rs4845617, rs2228145) genes were genotyped with the use of TaqMan SNP Genotyping Assays. No association of the polymorphisms from IL6 and IL6R genes with schizophrenia were found. We also investigated haplotypes in IL6 gene (consisting of rs1800795 and rs1800797) and in IL6R gene (consisting of rs4537545, rs2228145). We also found no preference in transmission of any haplotype. Our results do not support theory that polymorphisms of IL6 and IL6R genes are involved in the pathogenesis of schizophrenia. It seems advisable to carry out further examinations of the role of these polymorphisms in schizophrenia by means of TDT method and classical (case–control) association method.
    European Neuropsychopharmacology 09/2014; DOI:10.1016/S0924-977X(13)70674-6 · 5.40 Impact Factor